B12 deficiency and HbA1c are closely linked in ways that can significantly affect the accuracy of diabetes diagnosis and monitoring. The HbA1c test measures glycated haemoglobin over two to three months and relies on normal red blood cell turnover — a process directly disrupted by vitamin B12 deficiency. When B12 levels are insufficient, abnormal red cell production can render HbA1c results unreliable, potentially in either direction. This article explains the mechanism behind this interaction, identifies who is most at risk, and outlines UK guidance on when and how to use alternative glucose tests.

How B12 Deficiency Can Affect HbA1c Test Results

B12 deficiency disrupts red blood cell maturation, producing fewer, larger cells with an altered lifespan that can make HbA1c results spuriously high or low. UK guidance recommends fasting plasma glucose or OGTT when HbA1c reliability is in doubt.

The HbA1c test — formally known as glycated haemoglobin — is a cornerstone of diabetes diagnosis and long-term blood glucose monitoring. It works by measuring the percentage of haemoglobin molecules in red blood cells that have become bound to glucose over the preceding two to three months. Because the test relies on the lifespan and turnover of red blood cells, any condition that alters red cell production, size, or survival can directly influence the result.

Vitamin B12 (cobalamin) is essential for normal red blood cell maturation. When B12 levels are insufficient, the bone marrow produces fewer but larger red blood cells — a pattern known as megaloblastic anaemia. These abnormal cells have altered indices and a disrupted lifespan compared with healthy erythrocytes.

Importantly, the relationship between B12 deficiency and HbA1c is not straightforward. Published evidence indicates that B12 deficiency can make HbA1c unreliable, but the direction of the distortion — whether the result is spuriously high or spuriously low — is variable and may depend on the degree of anaemia, the specific HbA1c assay used, and other concurrent conditions. Clinicians and patients should therefore be aware that HbA1c is not always a reliable standalone marker when nutritional deficiencies or haematological conditions are present.

When HbA1c is considered unreliable, UK and WHO guidance recommends using fasting plasma glucose or a 75 g oral glucose tolerance test (OGTT) for diabetes diagnosis or assessment, as outlined in WHO 2011 guidance on the use of HbA1c in diabetes diagnosis and reflected in NICE NG28 (Type 2 Diabetes in Adults: Management).

Why HbA1c May Be Unreliable in B12 Deficiency

B12 deficiency alters red cell turnover and erythropoiesis, making HbA1c potentially unreliable in either direction — the distortion is variable and cannot be predicted. Clinicians should review the full blood count and consider alternative glucose tests.

The mechanism by which B12 deficiency distorts HbA1c centres on altered red blood cell turnover and erythropoiesis. In a healthy individual, red blood cells survive for approximately 120 days. During this time, glucose gradually attaches to haemoglobin in a process called glycation. Conditions that shorten red cell lifespan — such as haemolytic anaemia or acute blood loss — mean cells spend less time in circulation and accumulate less glycated haemoglobin, producing a spuriously low HbA1c even when blood glucose is elevated.

However, in megaloblastic anaemia caused by B12 or folate deficiency, the picture is more complex. Some evidence suggests that the production of fewer, larger, and longer-lived red cells may actually increase HbA1c, whilst other studies report a lowering effect. The direction of bias is therefore uncertain and variable, and should not be assumed to be consistently low. This uncertainty is recognised in laboratory medicine guidance from bodies such as the Association for Clinical Biochemistry and Laboratory Medicine (ACB) and the Royal College of Pathologists (RCPath).

It is also important to note that different conditions affect HbA1c in different ways:

• Haemolytic anaemia and acute blood loss shorten red cell lifespan and tend to lower HbA1c

• Iron deficiency anaemia is associated with increased HbA1c, likely due to prolonged red cell survival

• Haemoglobin variants (haemoglobinopathies) can cause variable or assay-dependent interference — the effect depends on the specific variant and the HbA1c method used

• B12 or folate deficiency alters erythropoiesis and red cell indices, making HbA1c potentially unreliable in either direction

Clinicians should therefore:

• Review the full blood count (FBC) alongside HbA1c

• Check serum B12 and folate when anaemia or macrocytosis (raised mean corpuscular volume, MCV) is identified

• Consider alternative glucose assessment methods — specifically fasting plasma glucose or a 75 g OGTT for diagnostic purposes, or self-monitored blood glucose (SMBG) or fructosamine/glycated albumin for interim monitoring when HbA1c is unreliable

Who Is Most at Risk of Both B12 Deficiency and Diabetes

People with type 2 diabetes on long-term metformin are at highest risk, as metformin impairs B12 absorption. Older adults, vegans, and those with gastrointestinal conditions or pernicious anaemia are also at elevated risk.

Certain patient groups face an elevated risk of developing both B12 deficiency and diabetes concurrently, making the interaction between these two conditions particularly relevant in clinical practice.

People with type 2 diabetes taking metformin represent one of the most important at-risk groups. Metformin, the first-line oral glucose-lowering agent recommended by NICE for type 2 diabetes (NG28), is well established as a cause of B12 malabsorption. It interferes with the absorption of the B12–intrinsic factor complex in the terminal ileum. Studies suggest that a significant proportion of long-term metformin users may develop biochemical B12 deficiency, though estimates vary widely depending on the population studied, the duration of use, and the B12 threshold applied. Clinical symptoms are not always apparent.

The MHRA Drug Safety Update on metformin and reduced vitamin B12 levels advises that B12 testing should be considered in patients who are symptomatic or who have risk factors for deficiency. NICE NG28 similarly recommends considering periodic monitoring of B12 in people at risk on long-term metformin — this is not a blanket recommendation for all metformin users, but is targeted at those with relevant risk factors or symptoms. Suspected adverse drug reactions, including possible metformin-associated B12 deficiency, can be reported via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk).

Older adults are at heightened risk of both conditions independently. B12 deficiency becomes increasingly common with age due to atrophic gastritis, reduced intrinsic factor production, and polypharmacy. Type 2 diabetes also rises sharply in prevalence after the age of 45.

Additional at-risk groups include:

• Vegans and strict vegetarians, who may have low dietary B12 intake

• People with autoimmune conditions, including pernicious anaemia or type 1 diabetes

• Individuals with gastrointestinal conditions such as Crohn's disease or coeliac disease, which impair nutrient absorption

• People who have undergone bariatric surgery, which can significantly reduce B12 absorption

• Long-term users of proton pump inhibitors (PPIs) or H2-receptor antagonists, which reduce gastric acid and impair B12 release from food

• Those with a family history of either pernicious anaemia or diabetes

For these groups, simultaneous monitoring of B12 status and glycaemic markers is particularly important to avoid diagnostic errors. Further guidance on assessment and management of B12 deficiency is available via NICE Clinical Knowledge Summary (CKS): Anaemia — B12 and folate deficiency.

UK Guidance on Interpreting HbA1c Alongside B12 Status

WHO 2011 guidance and NICE NG28 state that HbA1c should not be used for diagnosis when red blood cell turnover is abnormal; fasting plasma glucose or a 75 g OGTT should be used instead. Laboratory bodies advise documenting haematological conditions when requesting HbA1c.

UK and international guidance recognises that HbA1c has important limitations as a diagnostic and monitoring tool. WHO 2011 guidance on the use of HbA1c in the diagnosis of diabetes mellitus — adopted in the UK and reflected in NICE NG28 and NICE diabetes pathways — specifies that HbA1c should not be used for diagnosis when conditions affecting red blood cell turnover or haemoglobin are present. In such circumstances, fasting plasma glucose or a 75 g oral glucose tolerance test (OGTT) should be used instead.

NICE NG28 (Type 2 Diabetes in Adults: Management) and associated NICE pathways highlight that HbA1c results should be interpreted in the context of the patient's full clinical picture. When a full blood count reveals macrocytosis (enlarged red blood cells, indicated by a raised MCV), this should prompt investigation for B12 or folate deficiency before relying on HbA1c for diabetes management decisions.

From a laboratory medicine perspective, the Association for Clinical Biochemistry and Laboratory Medicine (ACB) and the Royal College of Pathologists (RCPath) advise that:

• HbA1c may be unreliable in the presence of haemolytic anaemia, haemoglobinopathies, or nutritional deficiencies affecting red cell biology — and the direction of distortion may be high or low

• Clinicians should document any known haematological conditions when requesting HbA1c, so laboratory staff can flag potential inaccuracies

• Serum B12 testing should be considered in patients on long-term metformin who are symptomatic or have risk factors for deficiency, in line with MHRA and NICE advice

• Alternative tests — fasting plasma glucose, OGTT, or interim use of fructosamine/glycated albumin — should be considered when HbA1c reliability is in doubt

The NHS website (nhs.uk) provides patient-facing information on the HbA1c test and factors that can affect its accuracy, which patients may find a useful starting point.

When to Retest HbA1c After Treating B12 Deficiency

HbA1c should not be repeated until at least three months after starting B12 replacement, once haematological recovery — normalisation of MCV and haemoglobin — has been confirmed. Interim glycaemic assessment should use fasting plasma glucose, OGTT, or self-monitored blood glucose.

Once B12 deficiency has been identified and treatment commenced, it is important to allow sufficient time for red blood cell populations to normalise before repeating HbA1c testing. Retesting too soon may still yield an inaccurate result, as the circulating red cell pool will not yet fully reflect normal cell turnover.

In the UK, B12 replacement is typically administered via intramuscular hydroxocobalamin injections for patients with confirmed deficiency, particularly those with malabsorption or pernicious anaemia, as specified in the BNF and NICE CKS guidance on B12 and folate deficiency anaemia. Oral cyanocobalamin supplementation may be appropriate in dietary deficiency where absorption is intact. Following initiation of treatment, the bone marrow begins producing normal-sized red cells relatively quickly — a reticulocyte response is typically seen within one to two weeks. However, full replacement of the circulating red cell pool takes approximately eight to twelve weeks, reflecting the normal red cell lifespan.

As a general clinical principle:

• Retest HbA1c no sooner than three months after commencing B12 replacement therapy, and ideally once haematological recovery has been confirmed

• Confirm haematological recovery — normalisation of MCV and haemoglobin — before interpreting the repeat HbA1c as reliable

• Use interim glucose monitoring — such as fasting plasma glucose, OGTT, or self-monitored blood glucose (SMBG) — to assess glycaemic control during the treatment period; fructosamine or glycated albumin may also be considered as short-term alternatives when HbA1c is unreliable

• Document the timing of B12 treatment initiation in the patient's records to contextualise any HbA1c results obtained during this period

This approach ensures that clinical decisions regarding diabetes diagnosis or medication adjustment are based on accurate data rather than a transiently distorted HbA1c result.

Talking to Your GP About B12 and Blood Sugar Monitoring

Patients on metformin, those with confirmed B12 deficiency, or those with unexpectedly low HbA1c results should discuss B12 monitoring and alternative glucose testing with their GP. Symptoms of anaemia, neuropathy, or hyperglycaemia warrant prompt medical review.

If you have been diagnosed with B12 deficiency, are taking metformin, or have recently been told your HbA1c result is unexpectedly low or inconsistent with your symptoms, it is worth raising this with your GP. Open communication about the potential interaction between B12 status and HbA1c accuracy can help ensure you receive the most appropriate monitoring and care.

You may wish to ask your GP the following questions:

• Has my B12 level been checked recently, particularly if I have been on metformin for more than a year, or if I have symptoms or risk factors for deficiency?

• Is my HbA1c result reliable, given any anaemia or nutritional deficiency I may have?

• Should I have additional glucose tests (such as a fasting blood glucose or glucose tolerance test) to complement or replace my HbA1c?

• When should my HbA1c be repeated after starting B12 treatment?

It is also important to be aware of symptoms that may suggest either worsening B12 deficiency or poorly controlled blood glucose, and to seek prompt medical advice if you experience:

• Persistent fatigue, breathlessness, or pallor (possible anaemia)

• Tingling, numbness, or weakness in the hands or feet (possible B12-related neuropathy)

• Unsteadiness when walking, or changes in memory or thinking (possible signs of more severe B12 deficiency requiring prompt assessment)

• Increased thirst, frequent urination, or unexplained weight loss (possible hyperglycaemia)

If you think you may be experiencing a side effect from a medicine — for example, symptoms of B12 deficiency that you believe may be related to metformin — you or your healthcare professional can report this via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Experiencing these side effects? Our pharmacists can help you navigate them →

Your GP can coordinate blood tests, review your medication, and refer you to a diabetes specialist or haematologist if needed. Proactive monitoring of both B12 and glycaemic status — particularly in higher-risk groups — is the most effective way to ensure that neither condition is inadvertently overlooked or mismanaged.

Frequently Asked Questions